<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04673422</url>
  </required_header>
  <id_info>
    <org_study_id>AMEDDengue2020</org_study_id>
    <nct_id>NCT04673422</nct_id>
  </id_info>
  <brief_title>Effect of Montelukast in Preventing Dengue With Warning Signs in Dengue Patients</brief_title>
  <official_title>Effect of Montelukast in Preventing Dengue With Warning Signs in Dengue Patients: a Multicenter Randomized, Double-blind, Placebo Controlled, Superiority Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Phramongkutklao College of Medicine and Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Phramongkutklao College of Medicine and Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study aims to determine the efficacy of montelukast in reducing the incidence of dengue&#xD;
      warning signs in adult dengue patients.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Dengue has been the growing public health problem in many tropical countries. Almost 4&#xD;
      billion people were estimated to be at risk, with estimated 400 million infections occurring&#xD;
      annually. In Asia, around 10% of febrile patients were virologically confirmed with dengue.&#xD;
      The most common cause of death is from dengue shock as a result of vascular leak syndrome.&#xD;
      This condition can occur in various clinical manifestations ranging from mild cases to&#xD;
      life-threatening condition of dengue shock syndrome. The common sites of plasma leakage are&#xD;
      pleural effusion and ascites. The contributing factors for endothelial dysfunction in dengue&#xD;
      are cytokines such as soluble tumor necrosis factor receptor (sTNFR/75), interferon gamma,&#xD;
      and vascular endothelial growth factor, NS1 antigenemia, complement activation, and&#xD;
      activation of dendritic cells, macrophages, and mast cells.&#xD;
&#xD;
      Mast cells have recently been acknowledged as an important regulator for promoting innate&#xD;
      immune responses. Important composition of granules in mast cells are proteases, chymase and&#xD;
      tryptase, histamine, heparin and leukotriene. The activated mast cells can undergo&#xD;
      degranulation, releasing these cytokines. These increase capillary permeability, leading to&#xD;
      vascular leakage.&#xD;
&#xD;
      Leukotriene has an important role in promoting plasma leakage and leukocyte adhesion in&#xD;
      postcapillary venules. In dengue patients, leukotriene levels usually elevate during febrile&#xD;
      and defervescence stage for 35 and 38 times of the baseline values, and return to baseline in&#xD;
      convalescence stage. Blocking leukotriene in dengue infected mice can significantly reduce&#xD;
      plasma leakage.&#xD;
&#xD;
      The management of dengue consists of only symptomatic treatment, and intravenous fluid&#xD;
      replacement. No specific treatment has yet been demonstrated of a benefit in preventing&#xD;
      complications. In the recent decades, mast cells have been demonstrated as a major&#xD;
      contributor of severe forms of dengue, leading to research in reduction of vascular&#xD;
      permeability with mast cell stabilizers or anti-histamine drugs. An animal model studies&#xD;
      found that a tryptase inhibitor, nafamostat, or leukotriene inhibitor, montelukast, could&#xD;
      reduce the plasma leakage.&#xD;
&#xD;
      In 2018, an open-label study found that patients with montelukast had a 22% absolute risk&#xD;
      reduction in dengue shock syndrome, compared to standard treatment. However, there has never&#xD;
      been any randomized controlled trial evaluating the efficacy of montelukast in dengue&#xD;
      patients.&#xD;
&#xD;
      This study aims to determine the efficacy of montelukast in reducing the incidence of dengue&#xD;
      warning signs in adult dengue patients.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 15, 2021</start_date>
  <completion_date type="Anticipated">February 28, 2024</completion_date>
  <primary_completion_date type="Anticipated">January 31, 2024</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>a randomized, prospective, 2-arm, parallel-group, double-blind, placebo-controlled superiority trial</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Rate of dengue with warning signs</measure>
    <time_frame>14 days or until the discontinuation of the follow up appointment by the attending physicians, whichever is shorter.</time_frame>
    <description>Rate of a composite outcome including&#xD;
abdominal tenderness or pain&#xD;
persistent vomiting&#xD;
clinical fluid accumulation&#xD;
mucosal bleeding&#xD;
liver enlargement &gt;2cm&#xD;
increase in hematocrit concurrent with decrease in platelet count However, lethargy will be excluded as a criterion for warning sign as almost all patients reported subjective lethargy.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Rate of each component of composite outcome of dengue with warning signs</measure>
    <time_frame>14 days or until the discontinuation of the follow up appointment by the attending physicians, whichever is shorter</time_frame>
    <description>Rate of each component of composite outcome of dengue with warning signs&#xD;
abdominal tenderness or pain&#xD;
persistent vomiting&#xD;
clinical fluid accumulation&#xD;
mucosal bleeding&#xD;
liver enlargement &gt;2cm&#xD;
increase in hematocrit concurrent with decrease in platelet count</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of hospitalization</measure>
    <time_frame>14 days or until the discontinuation of the follow up appointment by the attending physicians, whichever is shorter</time_frame>
    <description>Rate of admission to hospital</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Length of hospital stay</measure>
    <time_frame>up to 90 days</time_frame>
    <description>Length of hospital stay</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of severe dengue</measure>
    <time_frame>14 days or until the discontinuation of the follow up appointment by the attending physicians, whichever is shorter</time_frame>
    <description>Rate of a composite outcome including&#xD;
shock&#xD;
fluid accumulation with respiratory distress&#xD;
severe bleeding leading to hypotension or decreased hematocrit&#xD;
liver transaminase &gt;1000&#xD;
impaired consciousness&#xD;
heart and other organ failure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of dengue shock</measure>
    <time_frame>14 days or until the discontinuation of the follow up appointment by the attending physicians, whichever is shorter</time_frame>
    <description>Rate of hypotension or the pulse pressure of â‰¤ 20 mm Hg</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>30-day mortality</measure>
    <time_frame>30 days</time_frame>
    <description>death with in 30 days</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">358</enrollment>
  <condition>Dengue</condition>
  <condition>Dengue With Warning Signs</condition>
  <condition>Dengue Shock Syndrome</condition>
  <arm_group>
    <arm_group_label>Montelukast</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>a 10 mg tablet will be given orally immediately and every day thereafter for 10 days or until recovery, defined as the discontinuation of the follow up appointment by the attending physicians, whichever is shorter</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>a 10 mg tablet will be given orally immediately and every day thereafter for 10 days or until recovery, defined as the discontinuation of the follow up appointment by the attending physicians, whichever is shorter</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Montelukast</intervention_name>
    <description>A 10-mg tablet will be given orally immediately and every day thereafter for 10 days or until recovery, defined as the discontinuation of the follow up appointment by the attending physicians, whichever is shorter</description>
    <arm_group_label>Montelukast</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>A 10-mg tablet will be given orally immediately and every day thereafter for 10 days or until recovery, defined as the discontinuation of the follow up appointment by the attending physicians, whichever is shorter</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  at least 18 years old&#xD;
&#xD;
          -  diagnosis of dengue&#xD;
&#xD;
          -  positive NS1 antigen or polymerase chain reaction (PCR) test&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  any warning sign of dengue&#xD;
&#xD;
          -  concurrent diagnosis of other causes of fever, such as malaria or heat stroke&#xD;
&#xD;
          -  pregnancy&#xD;
&#xD;
          -  being unable to take medication by mouth&#xD;
&#xD;
          -  critical illness needing intubation or admission to an intensive care unit&#xD;
&#xD;
          -  being unable to communicate&#xD;
&#xD;
          -  other indication of montelukast&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Worapong Nasomsong, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Phramongkutklao College of Medicine and Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Worayon Chuerboonchai, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ananda Mahidol Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Vasin Vasikasin, MD</last_name>
    <phone>(+66) 2763-9300</phone>
    <phone_ext>93337</phone_ext>
    <email>vvasin@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Worapong Nasomsong, MD</last_name>
    <phone>(+66) 2763-9300</phone>
    <phone_ext>93337</phone_ext>
    <email>nasomsong.w@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Phramongkutklao Hospital</name>
      <address>
        <city>Bangkok</city>
        <zip>10400</zip>
        <country>Thailand</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Worapong Nasomsong, MD</last_name>
      <phone>(+66) 2763-9300</phone>
      <phone_ext>93337</phone_ext>
      <email>nasomsong.w@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Nattapat Nitinai, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ananda Mahidol Hospital</name>
      <address>
        <city>Lopburi</city>
        <zip>15000</zip>
        <country>Thailand</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Worayon Chuerboonchai, MD</last_name>
      <phone>(+66) 3678-5891</phone>
      <phone_ext>38065</phone_ext>
      <email>juicy.chompoo@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Vutthikorn Khingmontri, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Bawornnan Panuvatvanich, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Fort Suranari Hospital</name>
      <address>
        <city>Nakhon Ratchasima</city>
        <zip>30000</zip>
        <country>Thailand</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Thananut Bangchuad, MD</last_name>
      <email>thananutb@yahoo.com</email>
    </contact>
    <investigator>
      <last_name>Tanapol Roongfa-ngam, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Menanchaya Pongpricharoen, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Thailand</country>
  </location_countries>
  <link>
    <url>https://msptm.org/files/Vol35No4/1115-1122-Tania-Shakoori.pdf</url>
    <description>Ahmad A, Waseem T, Butt N, Randhawa F, Malik U, Shakoori T. Montelukast Reduces the Risk of Dengue Shock Syndrome in Dengue Patients. Tropical biomedicine. 2019;35:1115-22.</description>
  </link>
  <reference>
    <citation>Guzman MG, Gubler DJ, Izquierdo A, Martinez E, Halstead SB. Dengue infection. Nat Rev Dis Primers. 2016 Aug 18;2:16055. doi: 10.1038/nrdp.2016.55. Review.</citation>
    <PMID>27534439</PMID>
  </reference>
  <reference>
    <citation>L'Azou M, Moureau A, Sarti E, Nealon J, Zambrano B, Wartel TA, Villar L, Capeding MR, Ochiai RL; CYD14 Primary Study Group; CYD15 Primary Study Group. Symptomatic Dengue in Children in 10 Asian and Latin American Countries. N Engl J Med. 2016 Mar 24;374(12):1155-66. doi: 10.1056/NEJMoa1503877.</citation>
    <PMID>27007959</PMID>
  </reference>
  <reference>
    <citation>Wilder-Smith A, Ooi EE, Horstick O, Wills B. Dengue. Lancet. 2019 Jan 26;393(10169):350-363. doi: 10.1016/S0140-6736(18)32560-1. Review.</citation>
    <PMID>30696575</PMID>
  </reference>
  <reference>
    <citation>Srikiatkhachorn A, Krautrachue A, Ratanaprakarn W, Wongtapradit L, Nithipanya N, Kalayanarooj S, Nisalak A, Thomas SJ, Gibbons RV, Mammen MP Jr, Libraty DH, Ennis FA, Rothman AL, Green S. Natural history of plasma leakage in dengue hemorrhagic fever: a serial ultrasonographic study. Pediatr Infect Dis J. 2007 Apr;26(4):283-90; discussion 291-2.</citation>
    <PMID>17414388</PMID>
  </reference>
  <reference>
    <citation>Bethell DB, Flobbe K, Cao XT, Day NP, Pham TP, Buurman WA, Cardosa MJ, White NJ, Kwiatkowski D. Pathophysiologic and prognostic role of cytokines in dengue hemorrhagic fever. J Infect Dis. 1998 Mar;177(3):778-82.</citation>
    <PMID>9498463</PMID>
  </reference>
  <reference>
    <citation>Srikiatkhachorn A, Green S. Markers of dengue disease severity. Curr Top Microbiol Immunol. 2010;338:67-82. doi: 10.1007/978-3-642-02215-9_6. Review.</citation>
    <PMID>19802579</PMID>
  </reference>
  <reference>
    <citation>Green S, Vaughn DW, Kalayanarooj S, Nimmannitya S, Suntayakorn S, Nisalak A, Lew R, Innis BL, Kurane I, Rothman AL, Ennis FA. Early immune activation in acute dengue illness is related to development of plasma leakage and disease severity. J Infect Dis. 1999 Apr;179(4):755-62.</citation>
    <PMID>10068569</PMID>
  </reference>
  <reference>
    <citation>Avirutnan P, Punyadee N, Noisakran S, Komoltri C, Thiemmeca S, Auethavornanan K, Jairungsri A, Kanlaya R, Tangthawornchaikul N, Puttikhunt C, Pattanakitsakul SN, Yenchitsomanus PT, Mongkolsapaya J, Kasinrerk W, Sittisombut N, Husmann M, Blettner M, Vasanawathana S, Bhakdi S, Malasit P. Vascular leakage in severe dengue virus infections: a potential role for the nonstructural viral protein NS1 and complement. J Infect Dis. 2006 Apr 15;193(8):1078-88. Epub 2006 Mar 9.</citation>
    <PMID>16544248</PMID>
  </reference>
  <reference>
    <citation>Nascimento EJ, Silva AM, Cordeiro MT, Brito CA, Gil LH, Braga-Neto U, Marques ET. Alternative complement pathway deregulation is correlated with dengue severity. PLoS One. 2009 Aug 26;4(8):e6782. doi: 10.1371/journal.pone.0006782.</citation>
    <PMID>19707565</PMID>
  </reference>
  <reference>
    <citation>Londono-Renteria B, Marinez-Angarita JC, Troupin A, Colpitts TM. Role of Mast Cells in Dengue Virus Pathogenesis. DNA Cell Biol. 2017 Jun;36(6):423-427. doi: 10.1089/dna.2017.3765. Epub 2017 May 9. Review.</citation>
    <PMID>28486041</PMID>
  </reference>
  <reference>
    <citation>St John AL, Rathore AP, Yap H, Ng ML, Metcalfe DD, Vasudevan SG, Abraham SN. Immune surveillance by mast cells during dengue infection promotes natural killer (NK) and NKT-cell recruitment and viral clearance. Proc Natl Acad Sci U S A. 2011 May 31;108(22):9190-5. doi: 10.1073/pnas.1105079108. Epub 2011 May 16.</citation>
    <PMID>21576486</PMID>
  </reference>
  <reference>
    <citation>Schmutzler W, Bolsmann K, Zwadlo-Klarwasser G. Comparison of histamine release from human blood monocytes, lymphocytes, adenoidal and skin mast cells. Int Arch Allergy Immunol. 1995 May-Jun;107(1-3):194-6.</citation>
    <PMID>7542070</PMID>
  </reference>
  <reference>
    <citation>Marone G, Varricchi G, Loffredo S, Granata F. Mast cells and basophils in inflammatory and tumor angiogenesis and lymphangiogenesis. Eur J Pharmacol. 2016 May 5;778:146-51. doi: 10.1016/j.ejphar.2015.03.088. Epub 2015 May 2. Review.</citation>
    <PMID>25941082</PMID>
  </reference>
  <reference>
    <citation>St John AL, Rathore AP, Raghavan B, Ng ML, Abraham SN. Contributions of mast cells and vasoactive products, leukotrienes and chymase, to dengue virus-induced vascular leakage. Elife. 2013 Apr 30;2:e00481. doi: 10.7554/eLife.00481.</citation>
    <PMID>23638300</PMID>
  </reference>
  <reference>
    <citation>Syenina A, Jagaraj CJ, Aman SA, Sridharan A, St John AL. Dengue vascular leakage is augmented by mast cell degranulation mediated by immunoglobulin FcÎ³ receptors. Elife. 2015 Mar 18;4. doi: 10.7554/eLife.05291.</citation>
    <PMID>25783751</PMID>
  </reference>
  <reference>
    <citation>DahlÃ©n SE, BjÃ¶rk J, Hedqvist P, Arfors KE, HammarstrÃ¶m S, Lindgren JA, Samuelsson B. Leukotrienes promote plasma leakage and leukocyte adhesion in postcapillary venules: in vivo effects with relevance to the acute inflammatory response. Proc Natl Acad Sci U S A. 1981 Jun;78(6):3887-91.</citation>
    <PMID>6267608</PMID>
  </reference>
  <reference>
    <citation>Loke WM, Chow AY, Lam Mok Sing K, Lee CY, Halliwell B, Lim EC, Quek AM, Ooi EE, Seet RC. Augmentation of 5-lipoxygenase activity and expression during dengue serotype-2 infection. Virol J. 2013 Oct 30;10:322. doi: 10.1186/1743-422X-10-322.</citation>
    <PMID>24168271</PMID>
  </reference>
  <reference>
    <citation>Sherif NA, Zayan AH, Elkady AH, Ghozy S, Ahmed AR, Omran ES, Taha EA, Eldesoky EA, Ebied A, Tieu T, Maraie N, Kamel MG, Ngo HT, Mattar OM, Hirayama K, Huy NT. Mast cell mediators in relation to dengue severity: A systematic review and meta-analysis. Rev Med Virol. 2020 Jan;30(1):e2084. doi: 10.1002/rmv.2084. Epub 2019 Nov 10.</citation>
    <PMID>31709696</PMID>
  </reference>
  <reference>
    <citation>Rathore AP, Mantri CK, Aman SA, Syenina A, Ooi J, Jagaraj CJ, Goh CC, Tissera H, Wilder-Smith A, Ng LG, Gubler DJ, St John AL. Dengue virus-elicited tryptase induces endothelial permeability and shock. J Clin Invest. 2019 Jul 2;129(10):4180-4193. doi: 10.1172/JCI128426.</citation>
    <PMID>31265436</PMID>
  </reference>
  <reference>
    <citation>Leo YS, Gan VC, Ng EL, Hao Y, Ng LC, Pok KY, Dimatatac F, Go CJ, Lye DC. Utility of warning signs in guiding admission and predicting severe disease in adult dengue. BMC Infect Dis. 2013 Oct 24;13:498. doi: 10.1186/1471-2334-13-498.</citation>
    <PMID>24152678</PMID>
  </reference>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>December 9, 2020</study_first_submitted>
  <study_first_submitted_qc>December 15, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 17, 2020</study_first_posted>
  <last_update_submitted>January 31, 2021</last_update_submitted>
  <last_update_submitted_qc>January 31, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 3, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dengue</mesh_term>
    <mesh_term>Severe Dengue</mesh_term>
    <mesh_term>Shock</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Montelukast</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Data requests can be made anytime from 6 months after the publication of this trial. De-identified participant data can be requested by researchers for use in independent scientific research and will be provided following review and approval of the research proposal (including statistical analysis plan).</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_time_frame>starting 6 months after publication</ipd_time_frame>
    <ipd_access_criteria>De-identified participant data can be requested by researchers for use in independent scientific research and will be provided following review and approval of the research proposal (including statistical analysis plan). Requests should be sent to the corresponding author after publication.</ipd_access_criteria>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

